Categories: HealthcareNewsVaccine

Gritstone bio to Participate in Upcoming Investor Conferences

EMERYVILLE, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) — Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that management will be participating in the following investor conferences:

6th Annual Evercore ISI HealthCONx Conference (Fireside Chat)
Presentation Date and Time: Wednesday, November 29, 2023 at 10:00am ET
Speaker: Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive Officer
Location: Miami, FL

35th Annual Piper Sandler Healthcare Conference (Fireside Chat)
Presentation Date and Time: Thursday, November 30, 2023 at 10:00am ET
Speaker: Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive Officer
Location: New York, NY

First Annual Goldman Sachs Catalyst Clinic (Fireside Chat)
Presentation Date and Time: Tuesday, December 5 at 11:00am ET
Speaker: Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive Officer
Location: Virtual

Live webcasts of the fireside chats will be available via https://ir.gritstonebio.com/investors/events. Archived replays will be accessible for 30 days following each event.

About Gritstone bio
Gritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines. We leverage our innovative vectors and payloads to train multiple arms of the immune system to attack critical disease targets. Independently and with our collaborators, we are advancing a portfolio of product candidates to treat and prevent viral diseases and solid tumors in pursuit of improving patient outcomes and eliminating disease. www.gritstonebio.com

Gritstone Contacts
Investors:
George E. MacDougall
Gritstone bio, Inc.
ir@gritstone.com

Media:
Dan Budwick
1AB
(973) 271-6085
dan@1abmedia.com

Staff

Recent Posts

Hemogenyx Pharmaceuticals PLC Announces IRB Approval for Phase I Clinical Trial

Hemogenyx Pharmaceuticals Receives IRB Approval for Phase 1 Clinical Trial of HEMO-CAR-T (HG-CT-1)LONDON, UK /…

5 hours ago

Modular Medical Announces Pricing of $8.2 Million Public Offering

SAN DIEGO, CA / ACCESSWIRE / November 21, 2024 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular…

8 hours ago

Nicole Garrett and Under Pressure Hyperbarics Lead the Charge in Wellness Education With Immersive Events at L.A. Fashion Weekend and Beyond

BEVERLY HILLS, CALIFORNIA / ACCESSWIRE / November 21, 2024 / Nicole Garrett, CEO of Under…

11 hours ago

Beacon Healthcare Systems Expands Leadership Team with Addition of Ayman Mohamed as Chief Technology Officer

HUNTINGTON BEACH, Calif., Nov. 21, 2024 /PRNewswire/ -- Beacon Healthcare Systems, is pleased to announce…

14 hours ago

Talkiatry Ranked Number 6 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™

Attributes Revenue Growth to Innovative Partnerships, Strong Team, and Unique Value-Based Care Model NEW YORK,…

14 hours ago

Bright Light Imaging Leverages Alpha Nodus’s Gravity Auth, Enhanced by Integration with ADS’s MedicsRIS, to Streamline Patient Care

Automation That Makes a Difference SUNRISE, Fla., Nov. 21, 2024 /PRNewswire/ -- When it comes…

14 hours ago